HCW Biologics (HCWB) investor relations material

Executive summary

• Achieved $6.7 million in revenue for the six months ended June 30, 2026, primarily from a new license agreement with Beijing Trimmune Biotech Co. Ltd., including a $3.5 million cash payment and a $3.5 million equity interest.

• Preliminary Phase 1 data for HCW9302 in alopecia areata showed ≥25% reduction in SALT scores in all patients in the second dose cohort, with no dose-limiting toxicities or severe side effects; IND-enabling work for lead T-cell engager HCW11-018b is ongoing.

• Terminated the AlloTera Therapeutics license, re-acquired ex vivo rights to two molecules, and is seeking partners for commercialization as CAR-T therapy reagents.

• Completed $4.0 million and $1.6 million private placements in May and July 2026, respectively, with participation from directors and officers.

• Settled $2.8 million in overdue accounts payable, including $1.1 million to B & I Contractors and $1.7 million to Eirgenix, resulting in a $483,383 gain on extinguishment of liability.

Financial highlights

• Revenue rose to $6.7 million for the six months ended June 30, 2026, from $11,615 in the prior year period, driven by the Trimmune license.

• Net loss attributable to common stockholders was $13.4 million for the six months ended June 30, 2026, compared to $14.3 million in the prior year period.

• Operating expenses decreased 9% year-over-year to $2.5 million for R&D and 14% to $3.7 million for G&A in the first half of 2026.

• Cash and cash equivalents were $741,324 as of June 30, 2026, down from $1.95 million at year-end 2025.

• Cumulative net losses since inception reached $107.5 million as of June 30, 2026.

Outlook and guidance

• Expects continued operating losses and negative cash flows as clinical and preclinical programs advance.

• Plans to commercialize reagents HCW9201 and HCW9206 through a partnership in the second half of 2026.

• Full Phase 1 data for HCW9302 expected in Q4 2026; IND submission for HCW11-018b targeted for first half of 2027.

• Ongoing efforts to secure additional funding and manage working capital.

• Substantial doubt exists regarding ability to continue as a going concern for at least 12 months without additional funding.